Oric Pharmaceuticals, Inc. (ORIC)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

11.99 on 9 Oct 2026

0 buys3 sales at will11 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$129.47M

Free cash flow

$111.68M

Return on equity

-33.7%

Return on capital

-28.6%

Debt to equity

0.03

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
1 Oct 2026	Heyman Richard A. Director	Sold on a plan	$45.20K	8.4%
1 Oct 2026	Heyman Richard A. Director	Sold on a plan	$41.33K	1.5%
28 Sep 2026	Piscitelli Dominic Chief Financial Officer	Sold on a plan	$181.26K	16.1%
24 Sep 2026	Piscitelli Dominic Chief Financial Officer	Sold on a plan	$8.10K	0.9%
26 Aug 2026	Piscitelli Dominic Chief Financial Officer	Sold on a plan	$1.05M	52.4%
24 Jul 2026	Heyman Richard A. Director	Sold on a plan	$84.14K	15.5%

36out of 100

Profitability 0

Financial strength 80

Growth n/a

Insiders 35

Strongest on financial strength (80), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$2.77M

14 sales

Planned sales

79%

under a 10b5-1 plan